{"resourceType": "Evidence", "url": "https://fevir.net/resources/Evidence/55", "meta": {"versionId": "41", "lastUpdated": "2025-11-04T15:33:09.522Z"}, "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "55", "assigner": {"display": "Computable Publishing LLC"}}], "version": "4", "title": "14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)", "status": "active", "date": "2021-08-23T12:33:29.572Z", "approvalDate": "2020-12-17", "lastReviewDate": "2020-12-21", "publisher": "Computable Publishing LLC", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Brian S. Alper"}, {"name": "Joanne Dehnbostel"}, {"name": "Khalid Shahin"}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "description": "COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials)\nRisk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis\nRisk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysis", "assertion": "Remdesivir might reduce 14-day mortality, but this finding has not been repeated in a second trial (Low certainty)", "variableDefinition": [{"description": "Adults with COVID-19 pneumonia admitted to hospital", "variableRole": "population", "observed": {"reference": "Group/179799", "type": "Group", "display": "MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs (Biegel 2020 data 35/541 vs. 61/521) (Wang 2020 data 15/153 vs. 7/78) (SOLIDARITY data 219/2743 vs. 219/2708)"}, "intended": {"reference": "Group/12714", "type": "Group", "display": "COVID-19PneumoniaHospitalizedAdult"}, "directnessMatch": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/directness", "code": "high", "display": "High quality match between observed and intended variable"}]}}, {"description": "Remdesivir IV 200 mg once then 100 mg once daily for 9 days", "variableRole": "exposure", "observed": {"reference": "Group/179783", "type": "Group", "display": "Remdesivir IV 200 mg once then 100 mg once daily for 9 days"}, "intended": {"reference": "EvidenceVariable/12717", "type": "EvidenceVariable", "display": "Remdesivir"}}, {"description": "Placebo", "note": [{"text": "SOLIDARITY trial did not use placebo in control group"}], "variableRole": "exposure", "roleSubtype": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/variable-role", "code": "referenceExposure", "display": "reference exposure"}]}, "observed": {"reference": "EvidenceVariable/12718", "type": "EvidenceVariable", "display": "Placebo"}, "intended": {"reference": "EvidenceVariable/12718", "type": "EvidenceVariable", "display": "Placebo"}}, {"description": "Mortality at 14 days", "variableRole": "outcome", "observed": {"reference": "EvidenceVariable/12719", "type": "EvidenceVariable", "display": "Mortality at 14 days"}, "intended": {"reference": "EvidenceVariable/12719", "type": "EvidenceVariable", "display": "Mortality at 14 days"}}], "statistic": [{"description": "risk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect meta-analysis; Test for overall effect Z = 2.52 (p = 0.01); Heterogeneity Chi-squared = 7.33, df = 2 (p 0.03), I-squared = 73%", "statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000245", "display": "risk ratio"}]}, "quantity": {"value": 0.85}, "numberOfEvents": 779, "numberAffected": 779, "sampleSize": {"numberOfStudies": 3, "numberOfParticipants": 6774, "knownDataCount": 6744}, "attributeEstimate": [{"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000196", "display": "confidence interval"}]}, "level": 0.95, "range": {"low": {"value": 0.74}, "high": {"value": 0.96}}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000104", "display": "z-score"}]}, "quantity": {"value": 2.52}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000700", "display": "p-value"}]}, "quantity": {"value": 0.01}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000420", "display": "I-squared"}]}, "quantity": {"value": 0.73}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000419", "display": "Cochran's Q"}]}, "quantity": {"value": 7.33}, "attributeEstimate": [{"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000069", "display": "degrees of freedom"}]}, "quantity": {"value": 2}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000700", "display": "p-value"}]}, "quantity": {"value": 0.03}}]}], "modelCharacteristic": [{"code": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-model-code", "code": "effectsFixed", "display": "Fixed-effects"}]}, "applied": true}, {"code": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-model-code", "code": "metaAnalysis", "display": "Meta-analysis"}]}, "applied": true}]}, {"description": "risk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects meta-analysis; Test for overall effect Z = 1.44 (p = 0.15); Heterogeneity Chi-squared = 7.33, df = 2 (p 0.03), I-squared = 73%; Tau-squared = 0.04", "note": [{"text": "We consider the random-effects model more appropriate for interpretation as the true effect of remdesivir is likely different across the different populations represented in each trial."}], "statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000245", "display": "risk ratio"}]}, "quantity": {"value": 0.81}, "numberOfEvents": 779, "numberAffected": 779, "sampleSize": {"numberOfStudies": 3, "numberOfParticipants": 6774, "knownDataCount": 6744}, "attributeEstimate": [{"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000196", "display": "confidence interval"}]}, "level": 0.95, "range": {"low": {"value": 0.6}, "high": {"value": 1.08}}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000104", "display": "z-score"}]}, "quantity": {"value": 1.44}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000700", "display": "p-value"}]}, "quantity": {"value": 0.15}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000421", "display": "tau squared"}]}, "quantity": {"value": 0.04}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000420", "display": "I-squared"}]}, "quantity": {"value": 0.73}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000419", "display": "Cochran's Q"}]}, "quantity": {"value": 7.33}, "attributeEstimate": [{"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000069", "display": "degrees of freedom"}]}, "quantity": {"value": 2}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000700", "display": "p-value"}]}, "quantity": {"value": 0.03}}]}], "modelCharacteristic": [{"code": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-model-code", "code": "effectsRandom", "display": "Random-effects"}]}, "applied": true}, {"code": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-model-code", "code": "metaAnalysis", "display": "Meta-analysis"}]}, "applied": true}, {"code": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-model-code", "code": "tauDersimonianLaird", "display": "Dersimonian-Laird method"}]}, "applied": true}]}], "certainty": [{"description": "Low certainty due to inconsistency and risk of bias", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Overall", "display": "Overall certainty"}]}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "low", "display": "Low quality"}]}, "subcomponent": [{"type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "PublicationBias", "display": "Publication bias"}]}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "no-concern", "display": "no serious concern"}]}}, {"note": [{"text": "There is a high degree of heterogeneity (I-squared = 73%).  There is also inconsistency in findings between the fixed-effect and random-effects statistical models."}], "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Inconsistency", "display": "Inconsistency"}]}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "serious-concern", "display": "serious concern"}]}}, {"note": [{"text": "Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated  in certainty assessment."}], "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Imprecision", "display": "Imprecision"}]}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "no-concern", "display": "no serious concern"}]}}, {"type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Indirectness", "display": "Indirectness"}]}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "no-concern", "display": "no serious concern"}]}}, {"type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "RiskOfBias", "display": "Risk of bias"}]}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "serious-concern", "display": "serious concern"}]}, "subcomponent": [{"note": [{"text": "No blinding (no placebo control) in the largest trial"}], "type": {"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:00035", "display": "Inadequate blinding of participants"}], "text": "Lack of blinding"}, "rating": {"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "present", "display": "present"}]}}]}]}], "id": "55", "studyDesign": [{"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:01003", "display": "randomized assignment"}]}], "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en\"><p>[No data.]</p></div>"}, "relatesTo": [{"type": "derived-from", "targetMarkdown": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"}, {"type": "derived-from", "targetMarkdown": "Remdesivir for the Treatment of Covid-19 - Final Report"}, {"type": "derived-from", "targetMarkdown": "Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results"}], "citeAs": "14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, Joanne Dehnbostel, Khalid Shahin [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 55. Published 2020-12-17. Revised 2021-08-23. Available at: https://fevir.net/resources/Evidence/55. Computable resource at: https://fevir.net/resources/Evidence/55#json.", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code": "active", "display": "Active"}]}}], "name": "Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY"}